Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QBW251 dose-ranging add-on study in COPD patients on triple inhaled therapy
NL-OMON50119Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Icenticaftor in chronic obstructive pulmonary disease (COPD) (5 arms), sponsored by Novartis. Primary endpoint: Change from baseline in trough FEV1 at Week 12. Started Oct 2019; status: active, not recruiting.
02
Drugs
Icenticaftor
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NL-OMON50119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50119.